Sigyn Therapeutics (SIGY) Short term Debt (2024 - 2025)

Sigyn Therapeutics (SIGY) posted Short term Debt of $304637.0 for Q3 2025, up 16.25% sequentially from $262062.0 in Q2 2025.

Sigyn Therapeutics (SIGY) Short term Debt (2024 - 2025) Analysis & Trends

Sigyn Therapeutics has reported Short term Debt for 2 years, with the latest figure at $304637.0 in Q3 2025.

Quarterly Short term Debt changed N/A year-over-year to $304637.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $304637.0 (changed N/A YoY) and the FY2024 annual result came in at $174206.0, changed N/A from the prior year.
Short term Debt advanced to $304637.0 in Q3 2025 per SIGY's latest filing, from $262062.0 in the prior quarter.
Over five years, Short term Debt peaked at $304637.0 in Q3 2025 and troughed at $174206.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Sigyn Therapeutics	48,161.31	-37,409.69	-

Download Data